Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer

PURPOSE: This single-arm, open label Phase II study evaluated the safety and efficacy of taselisib (GDC-0032) plus fulvestrant in postmenopausal women with locally advanced or metastatic HER2-negative, hormone receptor (HR)-positive breast cancer. EXPERIMENTAL DESIGN: Patients received 6 mg oral tas...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Dickler, Maura N., Saura, Cristina, Richards, Donald A., Krop, Ian E., Cervantes, Andrés, Bedard, Philippe L., Patel, Manish R., Pusztai, Lajos, Oliveira, Mafalda, Cardenas, Alison K., Cui, Na, Wilson, Timothy R., Stout, Thomas J., Wei, Michael C., Hsu, Jerry Y., Baselga, José
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6139036/
https://ncbi.nlm.nih.gov/pubmed/29793946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0613
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker